Gerhard Siemeister - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Gerhard Siemeister

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Chemmedchem|September 30, 2017

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.

Journal of Medicinal Chemistry|April 28, 2020

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 KinaseVolker K Schulze, Ulrich Klar, Dirk Kosemund, et al.

Cell Reports|July 21, 2021

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSebastian M Dieter, Christine Siegl, Paula L Codó, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Chemmedchem|September 30, 2017

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.

Journal of Medicinal Chemistry|April 28, 2020

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 KinaseVolker K Schulze, Ulrich Klar, Dirk Kosemund, et al.

Cell Reports|July 21, 2021

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancerSebastian M Dieter, Christine Siegl, Paula L Codó, et al.

Pageof 4